IDEAYA Biosciences (IDYA) director awarded stock options on 20,000 shares

Rhea-AI Filing Summary

IDEAYA Biosciences, Inc. director Malcolm Garret Hampton received a grant of stock options covering 20,000 shares of common stock. The options have an exercise price of $30.57 per share and expire on June 16, 2036.

All 20,000 options vest in full on the earlier of the first anniversary of the grant date or immediately before the next Annual Meeting following the grant, as long as he continues serving on the board through the vesting date. This filing reflects a compensation-related award rather than an open-market trade.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Hampton Malcolm Garret

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	20,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 20,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 20,000 options Exercise price: $30.57 per share Underlying shares: 20,000 shares +2 more

5 metrics

Stock options granted 20,000 options Grant to director on June 16, 2026

Exercise price $30.57 per share Strike price for granted options

Underlying shares 20,000 shares Common stock underlying the options

Expiration date June 16, 2036 Option term end date

Post-grant option holdings 20,000 options Total derivative position following transaction

Key Terms

Stock Option (right to buy), exercise price, Annual Meeting, vest in full

4 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price: "30.5700""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Annual Meeting financial

"immediately prior to the Annual Meeting following the date of grant"

A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.

vest in full financial

"100% of the shares subject to the option shall vest in full"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hampton Malcolm Garret

(Last) (First) (Middle)

C/O IDEAYA BIOSCIENCES, INC.

5000 SHORELINE COURT, SUITE 300

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IDEAYA Biosciences, Inc. [ IDYA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$30.57	06/16/2026		A		20,000		(1)	06/16/2036	Common Stock	20,000	$0	20,000	D

Explanation of Responses:

1. 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date.

	/s/ Andres Ruiz Briseno, as Attorney-in-Fact for Malcolm Garret Hampton	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did IDEAYA Biosciences (IDYA) director Malcolm Garret Hampton report in this Form 4?

He reported receiving a grant of stock options for 20,000 IDEAYA common shares. These options are a compensation-related award, not an open-market trade, and give him the right to buy shares at a fixed exercise price in the future.

How many IDEAYA (IDYA) shares are covered by the new stock options?

The grant covers options on 20,000 shares of IDEAYA common stock. Each option represents the right to purchase one share, subject to vesting conditions and payment of the $30.57 per share exercise price when exercised.

What is the exercise price and expiration date of the IDEAYA (IDYA) options?

The options have an exercise price of $30.57 per share and expire on June 16, 2036. This means the director can choose to exercise the options at $30.57 any time after vesting and before the 2036 expiration date.

When do Malcolm Garret Hampton’s IDEAYA (IDYA) options vest?

All 20,000 options vest in full on the earlier of the first anniversary of the grant date or immediately before the next Annual Meeting. Vesting is contingent on his continued service on IDEAYA’s board through that vesting date, according to the disclosure.

Is this IDEAYA (IDYA) Form 4 a stock purchase or sale in the market?

No, the Form 4 reports a grant of stock options as compensation, not a market trade. The director did not buy or sell shares in the open market; he received options that may be exercised for shares in the future.